IVX-411
COVID-19 nanoparticle vaccine candidate
From Wikipedia, the free encyclopedia
IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Intramuscular |
In 2022 results were released that the RDB antigen component of the vaccine was unstable, which resulted in reduced potency.[5]
.svg){kind=small}
.png){kind=small}
